Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘CAR-macrophages’

Novel approaches to cell therapies – Part 1

In the first of a two part series on chimeric antigen receptor (CAR) cells, we take a look at some novel developments, not all of which are T cell based.

Can switchable CARs make a lasting impact?

Increasingly researchers are exploring the potential for novel approaches with other immune cells, as well as ways to potentially make cell therapies safer for patients using switchable technology.

What’s the skinny on these approaches and do they have some legs for the long term?

Here we take a look at some innovative ideas which caught our attention – not all of which may have a long term future…

To learn more about our ongoing post AACR21 reviews and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

New developments in tumour immunology and immunotherapy

This week I’ve been attending the excellent AACR Special Conference on Tumour Immunology and Immunotherapy here in Miami Beach. I must say that it’s really rather nice to have a local event literally less than 20 blocks away for once – it sure beats all the stress and hassle of long distance travel!

Were any of the early IO developments flying high in Miami Beach this week?

The meeting is designed to “integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.”

In this latest conference report, we cover some key highlights and insights learned, as well as review some early clinical data that was presented on several fronts including new companies and novel approaches to CAR-T cell therapy, as well as an important update on STING agonism.

We also identify some emerging trends that may teach us more about the future landscape developments in immuno-oncology.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!